Monsenso participates in MENTBEST – a European community-based and personalised digital intervention project

Monsenso participates in MENTBEST – a European community-based and personalised digital intervention project

The new European intervention project MENTBEST will deliver an innovative and comprehensive community-based intervention programme and a personalised digital application based on Monsenso’s solution to prevent and mitigate the mental health challenges associated with dramatic and rapid change in Europe. 

European societies are severely impacted by global trends such as war, economic crisis, climate changes, migration, pandemics, and ageing population. These megatrends can negatively affect people’s psychological health and wellbeing – with vulnerable groups being at particular risk. Thus scalable intervention programmes are needed to build resilience and enhance self-help competency to prevent mental illness.

Therefore, the European Union is funding the design and delivery of validated community-based interventions and innovative technologies to empower individuals from vulnerable groups to better manage mental health challenges associated with dramatic and rapid change in Europe. During the MENTBEST project, interventions will be delivered to communities in five different countries, namely Albania, Estonia, Greece, Ireland, and Spain. The project is led by the European Alliance Against Depression, and includes a consortium of 14 European partners with an extensive range of expertise. 

As part of the intervention project, an AI-enabled app based on Monsenso’s digital health platform will be developed and trialed to help prevent mental illness among high-risk groups, particularly migrants/refugees, older people, younger people, long-term unemployed, and those already struggling with their mental health. The goal of the AI-enabled personalised self-care program is to allow vulnerable people to use their long-term smartphone-generated data to support their mental health self-management. 

“The ambition of MENTBEST is to increase resilience and self-help competencies of people most often left behind in times of rapid and dramatic societal changes.”, explains Professor Ulrich Hegerl, MENTBEST Project Coordinator and President of the European Alliance Against Depression.

“Timely access to evidence-based support has the potential to empower vulnerable people to reduce the risk of developing mental illnesses. We are looking forward to participating in MENTBEST and expanding our platform to provide personalised, AI-driven self-care programs to people at high risk of facing difficulties with their mental health.”, says Thomas Lethenborg, CEO at Monsenso. 

The MENTBEST app will be trialed in Denmark, Germany, and Spain under the leadership of Professor Lars Kessing and Associate Professor Maria Faurholt-Jepsen from Mental Health Services of the Capital Region of Denmark.

“The project builds on our year-long research experience with digital mental health for more severe mental health illnesses. We see great potential in digital, data-driven mental health also for mild to moderate conditions and consequently look forward to driving the digital intervention part of the MENTBEST project with Monsenso”, says Maria Faurholt-Jepsen, Associate professor at Mental Health Services in the Capital Region of Denmark.

Project title: MENTBEST
Total budget: DKK 52.1 mio.
Net contribution to Monsenso: DKK 5.7 mio.
Duration: 5 years

About the partners
The project is led by the European Alliance Against Depression. The consortium entails leading experts in mental health promotion, resilience, wellbeing and primary prevention of disorders, mental disorders and suicide prevention, mental health in the workplace, mental health in children and adolescents, mental health in old age and experts in e-mental health and support technology, public policy, public education and evaluation. The consortium members are European Alliance Against Depression Ev, Instituto de Saúde Pública da Universidade do Porto (Portugal), Universidad Autónoma de Madrid (Spain), National Suicide Research Foundation (Ireland), Region Hovedstaden (Denmark), Det Nationale Forskningscenter for Arbejdsmiljø (Denmark), Eesti-Rootsi Vaimse Tervise ja Suitsidoloogia Instituut (Estonia), Stiftung Deutsche Depressionshilfe Und Suizidpraevention (Germany), Qendres Se Shendetit Dhe Mireqenies Komunitare (Albania), Katholieke Universiteit Leuven (Belgium), Pintail Ltd (Ireland), Kentro Erevnon Notioanatolikis Evropis Astiki Mi Kerdoskopiki Etaireia (Greece), and Fundacio Institut Hospital del Mar D’Investigacions Mèdiques (Spain).

Further information:
Thomas Lethenborg
Tel. +45 21 29 88 27

Certified Adviser:
Norden CEF A/S
John Norden
Tel. +45 20 72 02 00

Healthcare as a business case: Which importance is placed on societal impact vs economic impact?

Healthcare as a business case: Which importance is placed on societal impact vs economic impact?

Over the past decade, public spending on health in Denmark has been above the EU average. Due to the COVID-19 pandemic, government spending on healthcare has grown by more than 5% in 2020 alone [1], reaching total healthcare expenditures of DKK 270.794m in 2021 [2]. But how does Denmark decide which new treatment approaches to spend money on, and does the societal impact of healthcare measures play an equally important role as their economic impact?

Though member states of the European Union are not precluded from “releasing marketing authorisations valid at national level” for new medicines/treatments, EU-wide marketing authorisations require new treatments to go through a centralised authorisation procedure managed by the European Medicines Agency (EMA), which evaluates the pharmaceutical quality, safety, and efficacy of new treatments [3]. However, whereas obtaining marketing authorisation on an EU level allows providers to offer their new medicines/treatments, it is mainly the national health authorities’ decisions on reimbursement and pricing measures that affect if patients will have access to them [3]. 

In Denmark, the Danish Medicines Council (Medicinrådet) is an important body that assesses new treatment approaches and makes recommendations related to which medicines/treatments should be used in the Danish healthcare system [4]. Typically, cost-effectiveness and the impact on the healthcare budget are two important economic factors that national health authorities consider during such evaluations [3]. But what about the societal impact of new treatments? Does it receive sufficient consideration during the assessment procedures? 

Let’s take innovative digital health solutions as an example. If we purely consider the direct economic costs digital health solutions for mental health can help to reduce, such as the costs for (re)hospitalisation (e.g., DKK 6.000 per day), do we really get a full picture of the value of these innovations in healthcare? Potentially not, as the societal impact would not have been considered.

For instance, we would have not taken into account that digital health solutions for mental health can significantly improve the quality of life of individuals suffering from mental disorders [5], or that these innovations can enable mentally ill individuals to better recover and return to work faster. Neither would we have considered that digital solutions can facilitate making better use of resources available in the future, for instance by helping clinicians to handle growing patient data volumes they often feel overwhelmed with [6]. 

The societal impact of new treatments may be more difficult to quantify than the pure health economic impact, but we believe it is an important factor to consider when evaluating innovative approaches. At Monsenso, we have made it our mission to enable better mental health for more people at lower costs, and the positive societal impacts and increased quality of life that we help generate are as important to us as the pure health economic impact.
About Monsenso
Monsenso is an innovative technology company offering a digital health solution used for decentralised trials, remote patient monitoring and treatment support. Our mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data. Our solution helps optimise the treatment and gives a detailed overview of an individual’s health through the collection of outcome, adherence, and behavioural data. It connects individuals, carers, and healthcare providers to enable personalised treatment, remote care, and early intervention. We collaborate with health and social care, pharmaceuticals, and leading researcher worldwide in our endeavors to deliver solutions that fit into the life of patients and healthcare professionals. To learn more visit


[1] European Commission (2021). State of Health in the EU · Denmark · Country Health Profile 2021.

[2] Statistics Denmark (n.d.). Health care expenditure.

[3] European Parliament (2015). Towards a Harmonised EU Assessment of the Added Therapeutic Value of Medicines.

[4] Medicinrådet (n.d.). Danish Medicines Council.

[5] Monsenso (2022). Key research findings.

[6] Elsevier Health (2022). Clinician of the Future Report 2022.